Improving Diagnosis and Treatment of Metastatic Advanced Prostate Cancer
Launched by ROYAL MARSDEN NHS FOUNDATION TRUST · Jul 21, 2021
Trial Information
Current as of July 22, 2025
Unknown status
Keywords
ClinConnect Summary
Metastatic Advanced Prostate Cancer occurs when cancer spreads from the prostate to other parts of the body (bones, lymph nodes or other organs), with bones being the commonest site of spread in prostate cancer. These cancer growths are called metastases. APC metastases are diverse (heterogeneous) in their growth pattern, such that not all metastases will respond to the same treatment.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Retrospective study A Baseline WBMRI scans in metastatic APC patients acquired up to 8 weeks prior to the initiation of a new line of therapy.
- • Retrospective study B Paired WBMRI scans in metastatic APC patients at baseline within 8 weeks prior to treatment and at 12 ± 3 weeks after systemic treatment
- • Prospective study C Written informed consent. Age ≥18 years. Advanced prostate cancer patients with indication for systemic anti-cancer therapy to be enrolled in a clinical study.
- • Participants must have a baseline WBMRI and CT-guided bone marrow biopsy.
- Exclusion Criteria:
- • Prospective Study C Patient is claustrophobic. Contraindications to MRI examination (e.g., cardiac pacemakers, cochlear implants).
About Royal Marsden Nhs Foundation Trust
The Royal Marsden NHS Foundation Trust is a leading cancer treatment and research institution in the UK, renowned for its commitment to advancing oncology through innovative clinical trials and cutting-edge therapies. With a multidisciplinary team of experts, the Trust integrates patient care with groundbreaking research, fostering a collaborative environment to improve outcomes for cancer patients. As a pioneer in the field, the Royal Marsden actively contributes to the development of new treatment protocols and plays a critical role in translating scientific discoveries into clinical practice, ensuring that patients have access to the latest advancements in cancer care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sutton, Surrey, United Kingdom
Patients applied
Trial Officials
Nina Tunariu
Principal Investigator
The Royal Marsden NHS FT
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials